Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Jun
15
Today In Oncology
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
FDA Approval in Renal Cell Carcinoma Adjuvant Belzutifan With Pembrolizumab
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo